| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.2 | 1.2 |
| Gross profit | 0.1 | -0.1 |
| Profit before tax | -2.2 | -10.4 |
| Net income | -2.2 | -10.4 |
| EPS (diluted, $ a share) | $-0.95 | $-9.57 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -81.7% |
|---|---|
| Gross margin | 43.8% |
10-Q filed with the SEC, NYSE: PMI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Picard Medical, Inc.: key numbers
- Share price
- $7.24Close, Nov 16
- Market cap
- $19.3M
- Shares outstanding
- 2.66MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Picard Medical, Inc.
All →Picard Medical Leadership Change
Picard Medical, Inc. appointed Richard Fang, Ph.D., as its permanent Chief Executive Officer, effective October 28, 2026. Dr. Fang, who has served as Interim CEO since June 2024 and is the current Chairman of the Board, will receive an annual salary of $0.4 million with no new compensation awards granted at this time.
Picard Medical Other 8-K Filing
Picard Medical entered into a Warrant Amendment and Exchange Agreement to issue 200,000 shares of common stock in exchange for the surrender and cancellation of existing warrants. The transaction was conducted as a debt-free exchange under Section 3(a)(9) of the Securities Act, effectively discharging all anti-dilution and adjustment rights associated with the original warrants.
Picard Medical $1M Debt Financing with three accredited investors
Picard Medical, Inc. issued three unsecured convertible notes in the aggregate principal amount of $1.0 million to three accredited investors. The notes bear 3.0% interest and mature on September 30, 2027, with a conversion floor price of $4.00 per share. Upon conversion, the company will also issue pre-funded warrants to the holders on a one-for-one basis.
- Value
- $1M
- Counterparty
- three accredited investors
- Term
- 1 year